Published in Hormones (Athens) on August 21, 2012
The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer. PLoS One (2014) 0.83
PET and PET/CT with 68gallium-labeled somatostatin analogues in Non GEP-NETs Tumors. ScientificWorldJournal (2014) 0.81
Prospective evaluation of (68)Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative (131)I-whole body scan: comparison with (18)F-FDG PET-CT. Eur J Nucl Med Mol Imaging (2014) 0.78
(99m)Tc-labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer. Thyroid (2014) 0.76
Expression of somatostatin receptors may guide the use of somatostatin receptor imaging and therapy in differentiated thyroid cancer. Hormones (Athens) (2012) 0.75
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol (2003) 2.36
Variable behavior and complications of autologous bone marrow mesenchymal stem cells transplanted in experimental autoimmune encephalomyelitis. Exp Neurol (2011) 1.77
Chromogranin A polymorphisms are associated with hypertensive renal disease. J Am Soc Nephrol (2008) 1.68
N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol (2002) 1.59
Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology. Am J Hum Genet (2004) 1.58
Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol (2005) 1.57
Chromogranin A regulates renal function by triggering Weibel-Palade body exocytosis. J Am Soc Nephrol (2009) 1.55
Hand-assisted retroperitoneoscopic live donor nephrectomy in comparison to open and laparoscopic procedures: a prospective study on donor morbidity and kidney function. Transplantation (2004) 1.49
Prognostic value of chromogranin A in severe sepsis: data from the FINNSEPSIS study. Intensive Care Med (2012) 1.48
Dermatofibrosarcoma protuberans with fibrosarcomatous transformation of the head and neck. Head Neck Oncol (2011) 1.48
Letter to the Editor: Diffuse TTF-1 expression in a case of Merkel cell carcinoma. Pol J Pathol (2015) 1.40
Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med (2002) 1.40
Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg (2002) 1.35
Serum levels of 2,2',4,4',5,5'-hexachlorobiphenyl (CB-153) in relation to markers of reproductive function in young males from the general Swedish population. Environ Health Perspect (2003) 1.33
Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation (2007) 1.32
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer (2013) 1.32
Immunohistochemical distinction between merkel cell carcinoma and small cell carcinoma of the lung. Am J Dermatopathol (2006) 1.31
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis (2013) 1.28
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab (2006) 1.24
Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia. Clin Immunol (2005) 1.16
Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J Clin Endocrinol Metab (2003) 1.15
Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant (2007) 1.12
Well-differentiated extraskeletal osteosarcoma: report of 2 cases, 1 with dedifferentiation. Hum Pathol (2005) 1.12
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. PLoS One (2012) 1.12
Heritability and genome-wide linkage in US and australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure. Circulation (2008) 1.12
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res (2009) 1.09
Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest Ophthalmol Vis Sci (2011) 1.07
Naturally occurring human genetic variation in the 3'-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion. J Am Coll Cardiol (2008) 1.05
Volumetric and MGMT parameters in glioblastoma patients: survival analysis. BMC Cancer (2012) 1.05
Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of mice and rats. J Histochem Cytochem (2004) 1.03
Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology (2009) 1.03
Pilomyxoid astrocytoma of the cervical spinal cord in a child with rapid progression into glioblastoma: case report and literature review. Childs Nerv Syst (2010) 1.03
Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? Am J Gastroenterol (2012) 1.02
Development of abdominal fat and incipient metabolic syndrome in young healthy men exposed to long-term stress. Nutr Metab Cardiovasc Dis (2006) 1.02
Endocrine responses to nocturnal eating--possible implications for night work. Eur J Nutr (2003) 1.01
Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab (2006) 1.00
Neuroendocrine tumors of extrahepatic biliary tract. Pathol Oncol Res (2014) 1.00
Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. J Alzheimers Dis (2012) 0.99
Automated evaluation of Her-2/neu status in breast tissue from fluorescent in situ hybridization images. IEEE Trans Image Process (2005) 0.99
Primary primitive neuroectodermal tumor of the cervix confirmed with molecular analysis in a 23-year-old woman: A case report. Pathol Res Pract (2012) 0.98
Granins and granin-related peptides in neuroendocrine tumours. Regul Pept (2010) 0.98
Revisiting OCT4 expression in peripheral blood mononuclear cells. Stem Cells (2007) 0.98
Malignant gastric ghrelinoma with hyperghrelinemia. J Clin Endocrinol Metab (2004) 0.97
Enlargement of secretory vesicles by protein tyrosine phosphatase PTP-MEG2 in rat basophilic leukemia mast cells and Jurkat T cells. J Immunol (2002) 0.96
High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol (2004) 0.96
Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Cancer Control (2006) 0.95
Mixed corticomedullary adrenal carcinoma. Surg Today (2013) 0.95
A rare tumoral combination, synchronous lung adenocarcinoma and mantle cell lymphoma of the pleura. World J Surg Oncol (2008) 0.95
Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer. PLoS One (2013) 0.95
Associations between CB-153 and p,p'-DDE and hormone levels in serum in middle-aged and elderly men. Chemosphere (2006) 0.94
Natriuretic peptides in unstable coronary artery disease. Eur Heart J (2004) 0.93
Neuroendocrine inhibition of glucose production and resistance to cancer in dwarf mice. Exp Gerontol (2008) 0.93
Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin Exp Hypertens (2010) 0.93
Metabolic responses to nocturnal eating in men are affected by sources of dietary energy. J Nutr (2002) 0.93
Ciliated hepatic foregut cyst communicating with the gallbladder. Virchows Arch (2004) 0.92
An ancestral variant of Secretogranin II confers regulation by PHOX2 transcription factors and association with hypertension. Hum Mol Genet (2007) 0.92
Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocr Relat Cancer (2009) 0.92
OCT4B1 isoform: the novel OCT4 alternative spliced variant as a putative marker of stemness. Mol Hum Reprod (2009) 0.91
Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. Clin Breast Cancer (2012) 0.91
Enterobius vermicularis: a rare cause of appendicitis. Turkiye Parazitol Derg (2012) 0.91
Pain, disability and coping reflected in the diurnal cortisol variability in patients scheduled for lumbar disc surgery. Eur J Pain (2008) 0.91
POP levels in breast milk and maternal serum and thyroid hormone levels in mother-child pairs from Uppsala, Sweden. Environ Int (2009) 0.91
Severe eosinophilic cholangitis with parenchymal destruction of the left hepatic lobe due to hydatid disease. Pathol Int (2009) 0.90
Umbilical endosalpingiosis: a case report. J Med Case Rep (2010) 0.89
Differential diagnosis and treatment of primary, cutaneous, anaplastic large cell lymphoma: not always an easy task. Int J Hematol (2009) 0.89
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. Anticancer Res (2011) 0.89
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med (2012) 0.89
Cellular expression and specific intragranular localization of chromogranin A, chromogranin B, and synaptophysin during ontogeny of pancreatic islet cells: an ultrastructural study. Pancreas (2003) 0.89
Characteristics of human prostasomes isolated from three different sources. Prostate (2003) 0.89
Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer. Strahlenther Onkol (2014) 0.88
Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck. Anticancer Res (2009) 0.88
Cervical epidural plasmacytoma presenting as ascending paraparesis. Spine J (2011) 0.88
A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas. Neoplasia (2008) 0.88
Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin J Pain (2010) 0.88
A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis. Endocr Relat Cancer (2007) 0.88
Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. J Transl Med (2012) 0.88
Evaluation of FISH image analysis system on assessing HER2 amplification in breast carcinoma cases. Breast (2007) 0.87
Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer Invest (2008) 0.87
Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept (2004) 0.87
Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy). Am J Cardiol (2005) 0.87
Pleiotropic effects of novel trans-acting loci influencing human sympathochromaffin secretion. Physiol Genomics (2006) 0.86
Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Am J Pathol (2002) 0.86
Prohormone convertases 1/3, 2, furin and protein 7B2 (Secretogranin V) in endocrine cells of the human pancreas. Regul Pept (2007) 0.85
Insulin resistance after cardiopulmonary bypass in the elderly patient. Scand Cardiovasc J (2007) 0.85
Obestatin/ghrelin cells in normal mucosa and endocrine tumours of the stomach. Eur J Endocrinol (2009) 0.85
Cervical thymic cysts in adults. Thyroid (2011) 0.85
Co-expression of ghrelin and its receptor in pancreatic endocrine tumours. Clin Endocrinol (Oxf) (2007) 0.85
AMACR is associated with advanced pathologic risk factors in sporadic colorectal adenomas. World J Gastroenterol (2010) 0.85
Chromogranin A in the human gastrointestinal tract: an immunocytochemical study with region-specific antibodies. J Histochem Cytochem (2002) 0.84
The effect of subconjunctival ranibizumab on primary pterygium: a pilot study. Cornea (2010) 0.84